Sequent Scientific Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
VIYASH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.8 pts less than Nifty Microcap 250 and 2.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sequent Scientific Limited submitted its Q1 FY26 results on August 8, 2025, after a board meeting. On a consolidated basis, revenue from operations rose to ₹4,414.20 million from ₹3,902.10 million in the same quarter last year, a growth of about 13%. Profit before tax (before exceptional items) jumped sharply to ₹267.70 million from ₹120 million, and profit after tax nearly doubled to ₹175.70 million versus ₹90.50 million last year. Basic EPS more than doubled to ₹0.57 from ₹0.26. On a standalone basis, however, revenue declined to ₹410.70 million from ₹576.70 million, and standalone PAT fell to ₹33.70 million from ₹45 million. The company recorded ₹12.50 million in exceptional costs linked to a pending Composite Scheme of Amalgamation involving Sequent, Viyash Life Sciences, Symed Labs, and other entities.
Strong consolidated earnings growth, driven by margin expansion and operational improvement, is positive for shareholders. The weaker standalone performance and the still-pending amalgamation scheme with multiple pharma entities are items to watch, as the deal's closure could materially reshape the company.